Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1671 1672 1675
This examiner grants 75% of resolved cases
Cassandra Senn Grizer is an examiner in Tech Center 1600 and Art Unit 1600. The profile includes 8 resolved cases, which result in an allowance rate of 75.0 percent. This 75.0 percent rate serves as a baseline for practitioners to estimate the probability of a grant. With 8 resolved cases, the data provides an initial look at the examiner's tendencies in this biotechnology and organic chemistry center.
The data shows an interview lift of 18.8 percent. This figure indicates that conducting an interview is associated with an increased probability of allowance compared to the baseline of cases where no interview occurs. Practitioners may consider the 18.8 percent lift when deciding whether to engage in direct communication. This positive lift suggests that verbal advocacy can be a factor in the prosecution process for Art Unit 1600.
The median days to allowance for Grizer is 1129. This 1129-day timeline provides a benchmark for the expected duration of the prosecution process from filing to grant. The combination of the 75.0 percent allowance rate and the 18.8 percent interview lift offers a preliminary roadmap for applicants. Understanding these metrics, including the 1129-day median, helps in setting expectations for both timing and results.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18277879 | NOVEL BACTERIOPHAGE HAVING CLOSTRIDIUM PERFRINGENS-SPECIFIC BACTERICIDAL EFFECT AND ANTIBACTERIAL COMPOSITION COMPRISING SAME | Non-Final OA | CJ CheilJedang Corporation |
| 18035809 | ENGINEERED PROTEIN FOR RAPID, EFFICIENT CAPTURE OF PATHOGEN-SPECIFIC ANTIBODIES | Final Rejection | Massachusetts Institute of Technology |
| 18175852 | MANUFACTURING PROCESS FOR HIGH TITER ANTIBODY | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | Final Rejection | Gilead Sciences, Inc. |
| 18273053 | MICROTUBULE DESTABILIZER ADDITIVES TO INCREASE RECOMBINANT VIRAL VECTOR TITERS | Non-Final OA | Biogen MA Inc. |
| 18417379 | VACCINE | Non-Final OA | ASTRAZENECA AB |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | Final Rejection | ASTRAZENECA UK LIMITED |
| 18272115 | VACCINE COMPOSITIONS | Final Rejection | Oxford University Innovation Limited |
| 18686564 | MULTIVALENT VIRAL PARTICLES | Non-Final OA | CORNELL UNIVERSITY |
| 18271983 | COMPOSITIONS AND METHODS FOR THE GENETIC MANIPULATION OF THE INFLUENZA VIRUS | Non-Final OA | Duke University |
| 18553124 | Peptide of Norovirus Origin, Polynucleotide, Antibody, Composition, Method for Identifying Neutralizing Epitope for Norovirus | Non-Final OA | Denka Company Limited |
| 18461835 | PRODUCTION OF ELISA REAGENTS AND VACCINES BY 'ONE PROCESS' | Non-Final OA | KING ABDULAZIZ UNIVERSITY |
| 18283516 | IMMUNOGENIC COMPOSITIONS | Final Rejection | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC |
| 18271901 | REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE | Non-Final OA | The U.S.A., as Represented by The Secretary, Department of Health and Human Services |
| 18710727 | COVID-19 THERANOSTIC | Non-Final OA | Université libre de Bruxelles |
| 18272087 | HOMOLOGOUS ADENOVIRAL VACCINATION | Non-Final OA | Gritstone bio, Inc. |
| 18285148 | NANOGEL-COATED VACCINE | Final Rejection | HanaVax Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy